Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010
Lauri E. Markowitz,Susan Hariri,Carol Y. Lin,Eileen F. Dunne,Martin Steinau,Geraldine M. McQuillan,Elizabeth R. Unger +6 more
Reads0
Chats0
TLDR
Within 4 years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake, and the estimated vaccine effectiveness was high.Abstract:
Background. Human papillomavirus (HPV) vaccination was introduced into the routine immunization schedule in the United States in late 2006 for females aged 11 or 12 years with catch-up vaccination recommended for those aged 13-26 years. In 2010 3-dose vaccine coverage was only 32% among 13-17 year-olds. Reduction in the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6 -11 -16 and -18) will be one of the first measures of vaccine impact. Methods. We analyzed HPV prevalence data from the vaccine era (2007-2010) and the prevaccine era (2003-2006) that were collected during National Health and Nutrition Examination Surveys. HPV prevalence was determined by the Linear Array HPV Assay in cervicovaginal swab samples from females aged 14-59 years; 4150 provided samples in 2003-2006 and 4253 provided samples in 2007-2010. Results. Among females aged 14-19 years the vaccine-type HPV prevalence (HPV-6 -11 -16 or -18) decreased from 11.5% (95% confidence interval [CI] 9.2-14.4) in 2003-2006 to 5.1% (95% CI 3.8-6.6) in 2007-2010 a decline of 56% (95% CI 38-69). Among other age groups the prevalence did not differ significantly between the 2 time periods (P > .05). The vaccine effectiveness of at least 1 dose was 82% (95% CI 53-93). Conclusions. Within 4 years of vaccine introduction the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake. The estimated vaccine effectiveness was high.read more
Citations
More filters
Journal ArticleDOI
Sexually transmitted diseases treatment guidelines, 2015.
Kimberly A. Workowski,Gail Bolan +1 more
TL;DR: These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30-May 2, 2013.
Journal ArticleDOI
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Céline Bouchard,Constance Mao,Jesper Mehlsen,Edson D. Moreira,Yuen Ngan,Lone Kjeld Petersen,Eduardo Lazcano-Ponce,Punnee Pitisuttithum,Jaime Alberto Restrepo,Gavin Stuart,Linn Woelber,Yuh Cheng Yang,Jack Cuzick,Suzanne M. Garland,Warner K. Huh,Susanne K. Kjaer,Oliver Bautista,Ivan S. F. Chan,Joshua Chen,Richard Gesser,Erin Moeller,Michael Ritter,Scott Vuocolo,Alain Luxembourg +26 more
TL;DR: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV -6, 11, 16, and 18 that was noninferior to that generated by the qHPV Vaccine.
Journal ArticleDOI
Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics?
TL;DR: China is undergoing the cancer transition stage where the cancer spectrum is changing from developing country to developed country, with a rapidly increase cancer burden of colorectal, prostate, female breast cancers in addition to a high occurrence of infection-related and digestive cancers.
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Lauri E. Markowitz,Eileen F. Dunne,Mona Saraiya,Harrell W. Chesson,Curtis Cr,Julianne Gee,Joseph A. Bocchini,Elizabeth R. Unger +7 more
TL;DR: This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines.
Journal ArticleDOI
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.
Sarah Reagan-Steiner,David Yankey,Jenny Jeyarajah,Laurie D. Elam-Evans,James A. Singleton,C. Robinette Curtis,Jessica R. MacNeil,Lauri E. Markowitz,Shannon Stokley +8 more
TL;DR: Overall progress in vaccination coverage among adolescents, HPV vaccination coverage continues to lag behind Tdap and MenACWY coverage at state and national levels, but seven public health jurisdictions achieved significant increases in ≥1- or ≥3-dose HPV vaccination Coverage among females in 2014, demonstrating that substantial improvement in HPV vaccinations coverage is feasible.
References
More filters
Related Papers (5)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Céline Bouchard,Constance Mao,Jesper Mehlsen,Edson D. Moreira,Yuen Ngan,Lone Kjeld Petersen,Eduardo Lazcano-Ponce,Punnee Pitisuttithum,Jaime Alberto Restrepo,Gavin Stuart,Linn Woelber,Yuh Cheng Yang,Jack Cuzick,Suzanne M. Garland,Warner K. Huh,Susanne K. Kjaer,Oliver Bautista,Ivan S. F. Chan,Joshua Chen,Richard Gesser,Erin Moeller,Michael Ritter,Scott Vuocolo,Alain Luxembourg +26 more
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano,Joel M. Palefsky,Stephen E. Goldstone,Edson D. Moreira,Mary E. Penny,Carlos Aranda,Eftyhia Vardas,Harald Moi,Heiko Jessen,Richard J. Hillman,Yen Hwa Chang,Daron G. Ferris,Danielle Rouleau,Janine T. Bryan,J. Brooke Marshall,Scott Vuocolo,Eliav Barr,David Radley,Richard M. Haupt,Dalya Guris +19 more